Poolbeg Pharma's TOPICAL trial for POLB 001, a potential treatment to prevent cytokine release syndrome in multiple myeloma patients, passed an interim safety review allowing it to continue without changes. This milestone supports Cavendish's 'buy' rating and 19p price target, implying a 110% upside from the current 9.1p share price. Patient recruitment is ongoing, with more trial sites opening, and the expanded patent portfolio across multiple regions boosts potential pharma partner interest. The trial's progress is seen as a de-risking event, enhancing Poolbeg's prospects despite expected losses during development.
Poolbeg Pharma's trial progress is the subject, with Pluang market data as of Sep 24, 2026 20:44 WIB. Among 100 priced Health-sector US stocks tradable on Pluang, 50 rose and 47 fell today. Notable movers include Charles River Laboratories Intl. Inc (CRL) at USD 293.01 with a 5.65% increase, Ginkgo Bioworks Holdings Inc (DNA) at USD 8.99 rising 4.78%, and Twist Bioscience Corp (TWST) at USD 165.00 up 4.12%.
Analysts have mixed views on VICI Properties, a REIT focused on gaming and hospitality properties, with some lowering price targets due to refinancing costs and rent growth limits. Despite these concerns, the company maintains strong fundamentals inc...
Roth Capital upgraded Okta's price target from $155 to $235 and maintained a Buy rating following the company's new AI agent identity strategy unveiled at its Investor Summit. Okta aims to expand beyond traditional identity management by securing AI ...
Vecima Networks reported strong quarterly results with revenue of $64.04 million, surpassing the $55.69 million estimate, and earnings per share of $0.15, beating the $0.14 forecast. The company, a broadband technology provider for cable and fiber op...
Bank of America raised its price target for Okta Inc to $220 from $200 following the company's announcement of new AI-agent security and identity features at the Oktane 2026 conference. These enhancements include Agent SSO, runtime enforcement, and s...
Jefferies reaffirmed its $110 price target on Uber Technologies, highlighting the company's expanding Mobility product suite as a key driver for faster bookings growth and margin expansion. The broker expects Uber's adjusted EBITDA to grow over 25% t...
